Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Theratechnologies Inc (THTX)

Theratechnologies Inc (THTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,086
  • Shares Outstanding, K 45,980
  • Annual Sales, $ 81,760 K
  • Annual Income, $ -23,960 K
  • EBIT $ 10 M
  • EBITDA $ 13 M
  • 60-Month Beta 1.30
  • Price/Sales 0.92
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 237.78% ( +1.15%)
  • Historical Volatility 87.19%
  • IV Percentile 51%
  • IV Rank 21.75%
  • IV High 993.80% on 10/14/24
  • IV Low 27.66% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 29
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 282
  • Open Int (30-Day) 402

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 11/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +1,248,850.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5302 +12.40%
on 12/20/24
2.1800 -21.10%
on 01/07/25
+0.1000 (+6.17%)
since 12/17/24
3-Month
1.1200 +53.57%
on 11/27/24
2.1800 -21.10%
on 01/07/25
+0.4400 (+34.38%)
since 10/17/24
52-Week
1.0800 +59.26%
on 05/08/24
2.1800 -21.10%
on 01/07/25
-0.3200 (-15.69%)
since 01/17/24

Most Recent Stories

More News
Theratechnologies Provides Update on EGRIFTA SV® Supply

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Announces Resumed Production of EGRIFTA SV®

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV

HDL : 23.29 (+1.84%)
TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance

TH.TO : 2.55 (+2.00%)
THTX : 1.7200 (-0.58%)

Business Summary

Theratechnologies, Inc. is a pharmaceutical company focusing on the development of therapeutic peptide products with an emphasis on growth-hormone releasing factor peptides. It's main product EGRIFTA is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy which is...

See More

Key Turning Points

3rd Resistance Point 1.8099
2nd Resistance Point 1.7799
1st Resistance Point 1.7500
Last Price 1.7200
1st Support Level 1.6901
2nd Support Level 1.6601
3rd Support Level 1.6302

See More

52-Week High 2.1800
Fibonacci 61.8% 1.7598
Last Price 1.7200
Fibonacci 50% 1.6300
Fibonacci 38.2% 1.5002
52-Week Low 1.0800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar